Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company experienced a decline in revenue and net profit in the first half of 2025, primarily due to weak consumer demand, but there are signs of improvement in the third quarter [5][6] - The company is expanding its new media channels, with a notable performance in the internet segment, which saw a revenue increase of 15.14% year-on-year [6] - The company has established a competitive advantage through a full industry chain, excellent variety selection, and unique processing technologies [7][8] Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 300 million yuan, a decrease of 16.51% year-on-year, and a net profit of 65.56 million yuan, down 33.99% year-on-year [5] - The Q2 2025 revenue was 129 million yuan, a decline of 6.64% year-on-year, with a net profit of 7.18 million yuan, down 67.61% year-on-year [5] Market Expansion - The company is focusing on expanding its presence in provinces outside of Zhejiang through flagship stores and traditional channels, with positive sales results reported in July and August [6] - The internet channel's revenue growth is attributed to the development of new media channels, particularly influencer live streaming, which has attracted a younger customer base [6] Competitive Advantages - The company has developed a comprehensive industry chain model that ensures product safety and effectiveness, along with a resource library for superior medicinal materials [7][8] - Unique technologies for processing products, such as low-temperature supersonic airflow breaking and purification, enhance product quality and absorption rates [8] Future Projections - The revenue forecasts for 2025-2027 are adjusted to 697.14 million yuan, 777.59 million yuan, and 859.25 million yuan, with expected growth rates of 0.79%, 11.54%, and 10.50% respectively [8]
寿仙谷(603896):上半年互联网端表现较好,预计三季度业绩有望好转